these studies assessed the ability of des-asn5- [ d-trp8-d-ser13 ] -somatostatin ( d-ats-ss ) to selectively inhibit insulin release and produce a hyperglycemia sufficient to compensate for the original impairment . d-ats-ss at 0.017 micrograms/min inhibited basal insulin output ( delta = -38 +/- 6 % , p less than 0.005 ) and increased basal pancreatic glucagon output ( delta - +21 +/- 6 % , p less than 0.05 , n = 5 ) .
C0021641
insulin
C0020456
hyperglycemia